Supernus Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, focused on the development and commercialization of innovative therapies targeting central nervous system disorders, particularly epilepsy and migraine. With a robust pipeline aimed at addressing significant unmet medical needs, Supernus is strategically positioned for growth in the expanding CNS market. The company's commitment to enhancing patient outcomes not only reflects a dedication to improving quality of life but also represents an attractive opportunity for institutional investors seeking to leverage advancements in healthcare solutions. Show more

Location: 9715 KEY WEST AVENUE, ROCKVILLE, MD, UNITED STATES, 20850, Rockville, MD, 20850, USA | Website: https://www.supernus.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

2.761B

52 Wk Range

$29.16 - $57.65

Previous Close

$48.16

Open

$48.15

Volume

1,011,393

Day Range

$48.11 - $49.49

Enterprise Value

2.574B

Cash

151.4M

Avg Qtr Burn

-61.66M

Insider Ownership

4.27%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Qelbree (viloxazine hydrochloride) Details Mental health, Attention deficit hyperactivity disorder	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Namzaric Details Alzheimer's Dementia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONAPGO™ (apomorphine hydrochloride) injection (SPN-830) Details Parkinson's disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZURZUVAE (Zuranolone) (SAGE-217) Details Postpartum depression	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gocovri (Amantadine) Details Dyskinesia (Parkinson's disease)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trokendi XR® (topiramate) Details Prophylaxis of migraine	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XADAGO (safinamide) Details Parkinson's disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Osmolex ER (amantadine) Details PD (Parkinson's Disease)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MYOBLOC® (rimabotulinumtoxinB) Details Cervical Dystonia Sialorrhea	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APOKYN® (apomorphine hydrochloride injection) Details Advanced Parkinson’s disease (PD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gocovri (Amantadine) Details Parkinson's disease for OFF episodes	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zulresso (brexanolone) Details PPD (Postpartum depression)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPN-817 Details Epilepsy	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPN-820/821 Details Treatment Resistant Depression, Mental health, Major depressive disorder	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SAGE-319 Details Cognitive Dysfunction	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPN-443 (Stimulant Therapy) Details Attention-Deficit/Hyperactivity Disorder	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.